Swedish medtech start-up Capitainer announced that its qDBS card has scored highly in a major new study published in Clinica Chimica Actaon the advantages of volumetric microsampling DBS devices in monitoring of patients with phenylketonuria (PKU).
The study was necessary according to the authors, because although measurement of dried blood spot phenylalanine (Phe) is central to the monitoring of PKU patients today, the volume and hematocrit (hct) of the blood applied to conventional DBS cards fluctuates and significantly affects analytical results.
